{
    "Trade/Device Name(s)": [
        "VITROS Immunodiagnostic Products Intact PTH II Reagent Pack"
    ],
    "Submitter Information": "Ortho-Clinical Diagnostics",
    "510(k) Number": "K221197",
    "Predicate Device Reference 510(k) Number(s)": [
        "K070709"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CEW"
    ],
    "Summary Letter Date": "January 17, 2023",
    "Summary Letter Received Date": "January 17, 2023",
    "Submission Date": "August 14, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1545"
    ],
    "Regulation Name(s)": [
        "Parathyroid Hormone Test System"
    ],
    "Analyte Class(es)": [
        "endocrine",
        "chemistry"
    ],
    "Analyte(s)": [
        "Intact Parathyroid Hormone (iPTH)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (K2-EDTA)",
        "Plasma (lithium heparin)",
        "Plasma (sodium heparin)"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube",
        "Lithium heparin tube",
        "Sodium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "VITROS 3600 Immunodiagnostic System"
    ],
    "Method(s)/Technology(ies)": [
        "Sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Assay",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for VITROS Immunodiagnostic Products Intact PTH II Reagent Pack, an immunoassay for quantitative measurement of intact parathyroid hormone in serum and plasma using VITROS 3600 platform",
    "Indications for Use Summary": "Quantitative measurement of intact parathyroid hormone (iPTH) in human serum and plasma to aid in diagnosis of hyperparathyroidism, hypoparathyroidism, differential diagnosis of hypocalcemia or hypercalcemia, and for intraoperative measurement of iPTH levels.",
    "fda_folder": "Clinical Chemistry"
}